Astragalus / Vim Cancer Research Results

AG, Astragalus: Click to Expand ⟱
Features:

Astragalus — Astragalus (AG; typically Astragalus membranaceus root, “Huangqi”) is a traditional botanical immunomodulator composed of multiple bioactive fractions, notably astragaloside IV (AS-IV; triterpenoid saponin), Astragalus polysaccharides (APS; high–molecular-weight glycans), and flavonoids. It is best classified as a multi-constituent herbal drug (botanical) whose dominant functional identity is immune regulation with secondary inflammation- and stress-response tuning. Common abbreviations include AG, AS-IV, and APS. In oncology contexts it is most often positioned as adjunct/supportive care rather than a validated standalone anticancer agent.

Primary mechanisms (ranked):

  1. Immune modulation with enhanced innate/adaptive effector function (macrophage, NK, T-cell activity; context-dependent antitumor immunity)
  2. Checkpoint and tumor–immune interface modulation (e.g., PD-L1 downregulation reported for APS in some models)
  3. Inflammation pathway tuning (NF-κB and cytokine networks; bidirectional depending on immune context)
  4. Growth/survival signaling modulation (PI3K/Akt/mTOR and MAPK; model- and constituent-dependent)
  5. EMT/migration programs (Wnt/β-catenin axis suppression reported in some tumor models)
  6. Redox/stress-response effects (ROS buffering and NRF2 activation are commonly reported; may be protective rather than directly cytotoxic)

Bioavailability / PK relevance: Constituent-dependent. AS-IV has low oral bioavailability and limited systemic exposure in typical oral-use scenarios; APS are poorly absorbed and are more plausibly active via gut–immune signaling and downstream immunomodulation rather than direct tumor exposure. Extract variability (species, processing, standardization) is a major translational confounder.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use purified AS-IV or APS at concentrations unlikely to reflect achievable human plasma levels from typical oral extracts; immune-mediated and gut–immune mechanisms are often more plausible clinically than direct concentration-driven tumor cell cytotoxicity.

Clinical evidence status: Human evidence is strongest for adjunctive use alongside standard therapy (quality-of-life, fatigue, immune parameters, and some meta-analyses reporting improved response/toxicity profiles in specific settings). Robust evidence for standalone anticancer efficacy is not established.

Astragalus is an herb that has been used in traditional Chinese medicine for centuries.It has many purported health benefits, including immune-boosting, anti-aging and anti-inflammatory effects.
Astragalus (AG; commonly referring to Astragalus membranaceus root; major constituents: astragaloside IV [AS-IV], polysaccharides [APS], flavonoids) is a traditional botanical immunomodulator. Its dominant biology is immune modulation and stress-adaptive signaling, ranking conceptually as:
(1) immune activation/regulation (macrophage, NK, T-cell modulation),
(2) NF-κB and inflammatory pathway tuning,
(3) PI3K/Akt/mTOR and MAPK context-dependent signaling, and
(4) NRF2-mediated cytoprotection/antioxidant effects.
Bioavailability is variable and constituent-dependent; AS-IV has relatively low oral bioavailability, APS are high-molecular-weight and act largely via gut–immune interaction. Many in-vitro cancer studies use purified compounds at concentrations exceeding typical plasma levels. Clinical evidence exists primarily as adjunctive oncology support (quality-of-life, immune parameters); robust standalone anticancer efficacy is not established. Immune stimulation may enhance antitumor surveillance but effects are tumor- and context-dependent.

Astragalus (AG) — Cancer-Relevant Pathway Effects

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Immune Activation ↑ immune-mediated cytotoxicity (context-dependent) ↑ immune competence G Immunomodulation APS frequently show macrophage/NK/T-cell modulation in preclinical systems; clinical positioning is commonly adjunctive/supportive.
2 PD-1 / PD-L1 Axis ↓ PD-L1 (model-dependent); ↑ antitumor immunity ↔ R–G Immune checkpoint interface APS has been reported to reduce PD-L1–mediated immunosuppression in some tumor models; translation to clinical checkpoint therapy remains uncertain.
3 NF-κB Signaling ↓ NF-κB (tumor-promoting inflammation; context-dependent) ↔ / balanced activation R–G Inflammatory pathway tuning Commonly described as anti-inflammatory in many models, but immune-activation contexts can require transient inflammatory signaling.
4 PI3K/Akt/mTOR ↓ Akt/mTOR signaling (model-dependent) ↔ / survival support (context-dependent) R–G Anti-proliferative signaling Often demonstrated with purified constituents and/or higher in-vitro concentrations; may contribute to growth suppression in select models.
5 MAPK Axis ↓ ERK; ↑ JNK/p38 (stress/apoptosis; model-dependent) ↔ adaptive stress response R Stress-response reshaping Directionality varies by fraction (AS-IV vs APS vs flavonoids), tumor type, and dose.
6 Wnt / β-catenin and EMT ↓ Wnt/β-catenin; ↓ EMT; ↓ migration/invasion (model-dependent) ↔ G Anti-metastatic phenotype shift Reported in several preclinical models; relevance depends on whether adequate exposure and target engagement occur in vivo.
7 Glycolysis and HIF-1α ↓ glycolysis / ↓ lactate (model-dependent) ↔ R–G Metabolic downshift Metabolic effects are described in some models, but may be secondary to upstream signaling and inflammatory-state changes.
8 Angiogenesis ↓ pro-angiogenic signaling (model-dependent) ↔ G Anti-angiogenic tendency Evidence is preclinical and heterogeneous; may be indirect via NF-κB/cytokine modulation.
9 ROS Modulation ↓ ROS (dose-dependent) ↓ ROS (protective) P–R Redox buffering Can be supportive for normal-tissue protection; may be counterproductive if combined with therapies relying on oxidative cytotoxicity (context-dependent).
10 NRF2 Axis ↑ NRF2 (context-dependent) ↑ NRF2 (cytoprotection) R–G Antioxidant gene induction NRF2 activation can protect normal tissues but may also support tumor stress tolerance in some contexts; mechanistic centrality varies by fraction.
11 Chemosensitization ↑ chemo-sensitization reported (model-dependent) ↑ tolerance to toxicity (context-dependent) G Adjunct compatibility Clinical literature is mixed and highly formulation-specific; some meta-analyses suggest improved tolerance and response when combined with standard regimens in selected settings.
12 Clinical Translation Constraint Constituent variability; low AS-IV oral exposure; APS primarily gut–immune; in-vitro dosing often non-physiologic; interaction risk with immunosuppressants/anticoagulants — Heterogeneity / PK Most credible clinical role is adjunct/supportive care with careful attention to product standardization and drug–herb interaction risk.
TSF Legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr


Astragalus — In Alzheimer’s disease (AD) and broader neurodegeneration models, Astragalus fractions (notably AS-IV and flavonoids; sometimes APS indirectly) are most often described as cytoprotective via anti-inflammatory and antioxidant programs, with secondary support of pro-survival signaling and mitochondrial stability. Evidence is primarily preclinical; high-quality AD RCT efficacy remains unestablished.

Primary mechanisms (ranked):

  1. Oxidative stress reduction and cellular stress buffering (context-dependent)
  2. Neuroinflammation suppression (microglial and NF-κB-linked cytokine modulation)
  3. Pro-survival signaling support (e.g., PI3K/Akt in injury/neurodegeneration models; context-dependent)
  4. Mitochondrial stabilization and metabolic support (model-dependent)

Bioavailability / PK relevance: AS-IV systemic exposure is limited with typical oral dosing; CNS relevance depends on formulation and model. Many findings use purified compounds and dosing not directly comparable to common supplement use.

In-vitro vs systemic exposure relevance: Numerous neuronal studies employ concentrations/doses that may exceed achievable CNS exposure; interpretation should emphasize direction-of-effect rather than assuming clinical target engagement.

Clinical evidence status: Predominantly preclinical; insufficient robust AD-specific RCT evidence for disease-modifying benefit.

Astragalus (AG) — Alzheimer’s Disease (AD)-Relevant Effects

Rank Pathway / Axis AD Context TSF Primary Effect Notes
1 Oxidative Stress ↓ neuronal ROS (context-dependent) P–R Neuroprotection Often attributed to flavonoids/AS-IV in model systems; translation depends on exposure and disease stage.
2 Neuroinflammation ↓ microglial activation; ↓ inflammatory cytokines (model-dependent) R–G Anti-inflammatory Commonly framed through NF-κB-linked pathways in preclinical literature.
3 PI3K/Akt Survival Pathway ↑ neuronal survival signaling (context-dependent) G Pro-survival support Often studied in ischemia/toxicity paradigms rather than human AD pathology directly.
4 Mitochondrial Function ↑ mitochondrial stability (model-dependent) R–G Energy support Reported improvements in mitochondrial dynamics/oxidative injury markers in some models.
5 Clinical Translation Constraint No robust AD RCT efficacy data — Evidence gap Current evidence is insufficient to claim disease-modifying clinical benefit in AD.
TSF Legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Vim, Vimentin: Click to Expand ⟱
Source:
Type:
Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.

In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment.
The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression.

High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers.
Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence.
As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival.
- vimentin up-regulation is often used as a marker of EMT in cancer



Scientific Papers found: Click to Expand⟱
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
5431- AG,    Advances in research on the anti-tumor mechanism of Astragalus polysaccharides
- Review, Var, NA
AntiTum↑, TumCG↓, TumCI↓, Apoptosis↑, Imm↑, Bcl-2↓, BAX↑, Wnt↓, β-catenin/ZEB1↓, TumCG↓, miR-133a-3p↑, JNK↓, Fas↑, P53↑, P21↑, NOTCH1↓, NOTCH3↓, TumCP↓, TumCCA↑, GPx4↓, xCT↓, AMPK↑, Beclin-1↑, NF-kB↓, EMT↓, Vim↓, TumMeta↓, VEGF↓, EGFR↓, eff↑, eff↑, MMP↓, P-gp↓, MMP9↓, ChemoSen↑, SIRT1↓, SREBP1↓, TumAuto↑, PI3K↓, mTOR↓, Casp3↑, Casp9↑, CD133↓, CD44↓, CSCs↓, QoL↑,
1333- AG,    Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, Ki-67↓, TumCP↓, Snail↓, Vim↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓,
1097- AG,    Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin
- in-vitro, Nor, HMrSV5 - in-vivo, NA, NA
*EMT↓, *E-cadherin↑, *α-SMA↓, *Vim↓, *β-catenin/ZEB1↓, *Smad7↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 2,   GSH↓, 1,   c-Iron↑, 1,   lipid-P↑, 1,   ROS↑, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   AMPK↑, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   JNK↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   EMT↓, 2,   GSK‐3β↓, 1,   mTOR↓, 2,   NOTCH1↓, 2,   NOTCH3↓, 1,   PI3K↓, 2,   TumCG↓, 3,   Wnt↓, 3,  

Migration ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   miR-133a-3p↑, 1,   MMP9↓, 1,   Snail↓, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 3,   TumMeta↓, 1,   Vim↓, 3,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL12↑, 1,   IL2↑, 1,   Imm↑, 2,   NF-kB↓, 1,   PD-L1↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 4,   eff↑, 4,   MDR1↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   Ki-67↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   QoL↑, 2,  
Total Targets: 73

Pathway results for Effect on Normal Cells:


Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   Smad7↑, 1,   Vim↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: Vim, Vimentin
4 Astragalus
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:37  Target#:336  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page